Abilify Maintena® (aripiprazol) 960 mg er indisert for vedlikeholdsbehandling av schizofreni hos voksne pasienter som er stabilisert med aripiprazol.2
Video om hvordan Abilify Maintena 960mg annenhver måned administreres kommer snart. Inntil videre kan du se på denne brosjyren.
Les mer: bivirkningsrapportering
Les mer: Abilify Maintena®felleskatalogtekst
NO-ASMT-0006-2024.04
NO-AM2-2400013
-
Abilify Maintena® 960 mg SPC 04/2024, 4.2.
-
Abilify Maintena® 960 mg SPC 04/2024, 4.1.
-
Harlin M, Yildirim M, Such P et al. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. CNS Drugs 2023;37:337-50.
-
Kane JM, Sanchez R, Perry PP et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73:617–24.
-
Naber D, Hansen K, Forray C et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia Schizophren Res 2015;168:498-504.
-
Naber D, Baker R, Eramo A et al. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study. Schizophr Res 2018;192:205–10.
-
Kane JM, Zhao C, Johnsons BR et al. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ 2015;18:145–54.
-
Abilify Maintena® 960 mg SPC 04/2024, 4.8.